Severe Acute Respiratory Syndrome Coronavirus Infection of Human Ciliated Airway Epithelia: Role of Ciliated Cells in Viral Spread in the Conducting Airways of the Lungs by Sims, Amy C. et al.
JOURNAL OF VIROLOGY, Dec. 2005, p. 15511–15524 Vol. 79, No. 24
0022-538X/05/$08.000 doi:10.1128/JVI.79.24.15511–15524.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Severe Acute Respiratory Syndrome Coronavirus Infection of Human
Ciliated Airway Epithelia: Role of Ciliated Cells in Viral Spread
in the Conducting Airways of the Lungs
Amy C. Sims,1* Ralph S. Baric,1,2 Boyd Yount,1 Susan E. Burkett,3 Peter L. Collins,4
and Raymond J. Pickles2,3
Departments of Epidemiology1 and Microbiology and Immunology,2 and Cystic Fibrosis/Pulmonary Research and Treatment
Center,3 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, and Respiratory Viruses Section,
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland4
Received 11 July 2005/Accepted 26 September 2005
Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in 2002 as an important cause of
severe lower respiratory tract infection in humans, and in vitro models of the lung are needed to elucidate
cellular targets and the consequences of viral infection. The SARS-CoV receptor, human angiotensin 1-con-
verting enzyme 2 (hACE2), was detected in ciliated airway epithelial cells of human airway tissues derived from
nasal or tracheobronchial regions, suggesting that SARS-CoV may infect the proximal airways. To assess
infectivity in an in vitro model of human ciliated airway epithelia (HAE) derived from nasal and tracheobron-
chial airway regions, we generated recombinant SARS-CoV by deletion of open reading frame 7a/7b (ORF7a/
7b) and insertion of the green fluorescent protein (GFP), resulting in SARS-CoV GFP. SARS-CoV GFP
replicated to titers similar to those of wild-type viruses in cell lines. SARS-CoV specifically infected HAE via
the apical surface and replicated to titers of 107 PFU/ml by 48 h postinfection. Polyclonal antisera directed
against hACE2 blocked virus infection and replication, suggesting that hACE2 is the primary receptor for
SARS-CoV infection of HAE. SARS-CoV structural proteins and virions localized to ciliated epithelial cells.
Infection was highly cytolytic, as infected ciliated cells were necrotic and shed over time onto the luminal
surface of the epithelium. SARS-CoV GFP also replicated to a lesser extent in ciliated cell cultures derived from
hamster or rhesus monkey airways. Efficient SARS-CoV infection of ciliated cells in HAE provides a useful in
vitro model of human lung origin to study characteristics of SARS-CoV replication and pathogenesis.
Infection of human respiratory airways by classic human
coronaviruses (HCoV) (e.g., HCoV-229E and HCoV-OC43)
typically produces mild common cold symptoms, although
more serious disease has been reported to occur in infants and
individuals with underlying comorbidities (42). However, in-
fection by a recently emerged HCoV can lead to a fatal pneu-
monia characterized as severe acute respiratory syndrome
(SARS), and the newly identified HCoV is designated SARS
coronavirus (SARS-CoV) (11, 25). SARS-CoV has caused
about 8,000 cases and 800 deaths worldwide, with an 10%
overall mortality rate prior to successful containment of the
epidemic. SARS-CoV has been isolated from humans, civet
cats, raccoon dogs, bats, and swine, suggesting that several
animal species may function as natural reservoirs for future
outbreaks (17, 28). In some cases, humans may display mild
disease, raising the possibility for asymptomatic carriage and
maintenance of virus in human populations (22, 52). The
SARS-CoV discovery also led to the identification of two new
HCoV, HCoV-NL63 and HCoV-HKU1, both of which are
associated with more-serious lower respiratory tract infections
in humans (62, 67). Given the growing importance of HCoV as
pathogens that produce severe human respiratory diseases,
relevant model systems are needed to elucidate the underlying
molecular mechanisms governing coronavirus pathogenesis
and virulence in the human lung. SARS-CoV infection is an
attractive model for HCoV infection, as it produces severe
disease in the human lung, it replicates efficiently in vitro, a
molecular clone is available to identify the genetic determi-
nants governing pathogenesis and virulence, and a variety of
animal models are under development (16, 34, 41, 44, 45, 70).
The SARS-CoV virion contains a single-stranded, positive-
polarity, 29,700-nucleotide RNA genome bound by the nucleo-
capsid protein (N). The capsid is packaged by a lipid bilayer
containing at least three structural proteins, including a 180-
kDa spike glycoprotein (S) that interacts with human angio-
tensin 1-converting enzyme 2 (hACE2) to mediate viral entry
into cells (30). In addition to the 23-kDa membrane glycopro-
tein (M), the envelope (E) protein is likely essential for effi-
cient virion maturation and release. More recently, open read-
ing frame 3a (ORF3a) was shown to encode a fourth virion
protein, although its functions in maturation and release are
unknown (72). The SARS-CoV genome contains nine ORFs,
the first of which encodes the viral replicase proteins required
for subgenomic- and genome-length RNA synthesis and virus
replication (see Fig. 2A) (32, 46, 48). Based on studies with
other coronaviruses, it is likely that SARS-CoV uses a tran-
scription attenuation model to synthesize both full-length and
subgenomic-length negative-strand RNAs containing antile-
ader RNAs, which then function as templates for the synthesis
of like-sized mRNAs (2, 49, 50). ORF2 to ORF8 are located
on eight subgenomic mRNAs synthesized as a nested set of 3
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coterminal RNA species in which the leader RNA sequences
on the 5 end of the genome are joined to body sequences at
distinct transcription regulatory sequences containing a highly
conserved consensus sequence (53, 59, 70). The SARS-CoV
consensus sequence is ACGAAC (32, 46, 53, 59, 70). The
virion structural gene products S, the ORF3a protein, M, E,
and N are encoded in mRNA transcripts 2, 3, 4, 5, and 9a,
respectively, while the group-specific ORFs are located on
mRNAs 3, 6, 7, 8 and 9. Interspaced among the SARS-CoV
structural genes are the group-specific genes (ORF3b, ORF6,
ORF7a/7b, ORF8a/8b, and ORF9b), which are not conserved
in other coronaviruses and whose functions in replication and
pathogenesis are generally unknown (32, 46, 53). Group-spe-
cific ORFs from other coronaviruses, such as mouse hepatitis
virus, feline infectious peritonitis virus, and transmissible gas-
troenteritis virus, usually encode luxury functions for replica-
tion in vitro (9, 10, 66). In the case of these viruses, group-
specific genes can be deleted, oftentimes attenuating
pathogenesis in vivo (9, 10, 18). The development of a molec-
ular clone for SARS-CoV provides a useful tool to study rep-
lication and pathogenesis by allowing direct manipulation of
the viral genome (70).
The predominant pathological features of SARS-CoV infec-
tion of the human lung include diffuse alveolar damage, atyp-
ical pneumonia with dry cough, persistent fever, progressive
dyspnea, and in some cases acute exacerbation of lung func-
tion. Major pathological lesions include inflammatory exuda-
tion in the alveoli and interstitial tissue, with hyperplasia of
fibrous tissue and fibrosis (5, 25, 27). In tissues isolated from
fatal cases of SARS-CoV, virus was localized by fluorescence
in situ hybridization within alveolar pneumocytes (primarily
type II) and within alveolar spaces. Pathological assessment of
histological samples of airway regions other than the alveolus
have been less rigorously studied, as the alveolar regions have
consistently demonstrated the most significant disease in late-
stage fatal cases (7, 60). However, there are now several re-
ports that examined early disease associated with SARS-CoV
infection which noted marked bronchiolar disease with respi-
ratory epithelial cell necrosis, loss of cilia, squamous cell meta-
plasia, and intrabronchiolar fibrin deposits. In fact, it has been
suggested that early diffuse alveolar damage as a result of
SARS-CoV infection may actually initiate at the level of the
respiratory bronchioles (13, 39).
We have previously described the use of an in vitro model of
human airway epithelium that recapitulates the morphological
and physiological features of the human airway epithelium in
vivo (43, 74). By use of this model, it has been shown that
common human respiratory viruses, e.g., human respiratory
syncytial virus (RSV) and human parainfluenza virus type 3
(PIV3), exclusively infect ciliated cells after intraluminal inoc-
ulation, raising the possibility that these cells play a major role
in pathogenesis of respiratory virus infection. Here, we test the
ability of SARS-CoV to infect human ciliated airway epithelia
(HAE) in vitro to determine whether infection and spread of
SARS-CoV throughout the ciliated conducting airway epithe-
lium may provide a valid model for understanding the patho-
genesis of SARS-CoV lung disease. To aid assessment of
SARS-CoV infection of HAE, we have generated a recombi-
nant clone of the Urbani strain of SARS-CoV that expresses
green fluorescent protein (GFP), SARS-CoV GFP, to allow
infection and spread to be monitored over time. We demon-
strate that SARS-CoV infects ciliated airway epithelial cells via
an interaction with hACE2 on the apical surface of ciliated
cells. Although progeny virus was initially shed into the luminal
compartment of the epithelium, at later times postinfection,
virus was also shed into basolateral compartments. Since cili-
ated airway epithelial cells possess unique physiological and
innate defense functions in the human lung (e.g., mucociliary
clearance), it is important to identify the ciliated cell tropism of
SARS-CoV and the pathological consequences of infection of
these cells.
MATERIALS AND METHODS
Construction of SARS-CoV GFP recombinant virus. To replace ORF7a/7b
with GFP, primer sets (i) no. 47 (5-GTGCTTGCTGTTGTCTACAG-3) and
SARS Mu6 (5-ATCGATCACCTGCCATGTTCGTTTTATGGATAATCTAA
CTCCATAGGTTC-3) and (ii) SARS Mu7 (5-ATCGATTTAATTAAGAGC
TCACTTTAATTGACTTCTATTTGTG-3) and 3-Ngl() (5-CTTTGCTCTC
AAGCTGGTTC-3) were used to generate amplicons flanking nucleotides
27,304 to 27,671 in the SARS-CoV genome. The amplicons were digested with
ClaI to create a cassette in which ORF7a/7b was removed, making available
AarI, ClaI, and PacI restriction sites. An AvrII cut amplicon was purified and
ligated back into the SARS-CoV F cDNA clone (70), systematically deleting
nucleotides 27,276 to 27,643 and inserting an AarI, ClaI, and PacI multiple
cloning site in the SARS-CoV genome. The sequence-confirmed F fragment was
used as the base plasmid for GFP insertion. A GFP amplicon was generated
using primers 5GFP() (5-CACCTGCTAAACGAACAAATTAAAATGGT
GAGCAAGGGCGAGGAG-3) and 3GFP() (5-TTAATTAATTACTTGT
ACAGCTCGTCCATGC-3). The GFP amplicon was then subcloned into the F
fragment missing the ORF7a/7b sequence by use of the AarI and PacI restriction
sites and sequenced, and this mutant F fragment was used to build the SARS-
CoV GFP.
To assemble full-length SARS-CoV GFP cDNA, the SARS A through F
inserts were restricted, separated through 0.8% agarose gels, visualized with a
Dark Reader light box (Claire Chemical), excised, and purified using a Qiaex II
DNA purification kit. The A through F fragments were ligated overnight, phe-
nol-chloroform extracted, and precipitated with isopropyl alcohol. Full-length
transcripts were generated in vitro as described by the manufacturer (mMessage
mMachine; Ambion) with certain modifications. To produce full-length capped
SARS-CoV N gene mRNA transcripts, 1 g of plasmid DNA encoding the N
gene forward primer (5-NNGGCCTCGATGGCCATTTAGGTGACACTATA
GATGTCTGATAATGGACCCCAATC-3) and reverse primer (5-NNNTTTT
TTTTTTTTTTTTTTTTTTTTTTATGCCTGAGTTGAATCAGCAG-3) was
transcribed by SP6 RNA polymerase with a 2:1 ratio of cap analog to GTP.
Full-length RNA transcripts were transfected into 800 l of Vero E6 cells (8.0
 106) in an electroporation cuvette, and four electrical pulses of 450 V at 50 F
were given with a Gene Pulser II electroporator (Bio-Rad), similarly to ap-
proaches previously described by our laboratory (70, 71). The transfected Vero
E6 cells were seeded in a 75-cm2 flask, incubated at 37°C, and monitored for
GFP fluorescence. Clonal virus progeny were then isolated by plaque assay and
monitored for GFP expression by fluorescence with an Olympus IX51 Research
inverted microscope.
Growth curve analysis in cell lines. To determine viral titers, samples were
taken at 2, 8, 12, 16, 20, and 32 h postinfection and assessed by plaque assay.
Briefly, supernatants from infected plates of Vero E6, MA104, and Caco-2 cells
were serially diluted, inoculated onto Vero E6 cell monolayers in 60-mm dishes,
and overlaid in complete media plus 0.8% agarose, and plaques were visualized
at 48 h via neutral red staining.
Northern blot analysis. Cultures of Vero E6 cells were inoculated with wild-
type Urbani, infectious-clone SARS-CoV (icSARS-CoV), and SARS-CoV GFP
at a multiplicity of infection of 1 for 1 h at 37°C. At 12 h postinfection, intra-
cellular RNA was isolated using RiboPure reagents as directed by the manufac-
turer (Ambion, Austin, TX). mRNA was isolated using QIAGENs Oligotex
mRNA spin column reagents according to the manufacturer’s instructions (QIA-
GEN, Valencia, CA). The mRNA was treated with glyoxal and separated on
agarose gels by use of NorthernMax-Gly according to the manufacturer’s instruc-
tions (Ambion, Austin, TX). The RNA was transferred to a BrightStar-Plus
membrane (Ambion) for 4 to 5 h, and the RNA was cross-linked to the mem-
brane by UV light. The blot was prehybridized and probed with an N-gene-
specific oligodeoxynucleotide probe (5-CTTGACTGCCGCCTCTGCTbTbCCC
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TbCTbGCb-3), where biotinylated nucleotides are designated with a superscript
b. Blots were hybridized overnight and washed with low- and high-stringency
buffers as recommended by the manufacturer. Filters were incubated with
streptavidin-AP, washed, and then incubated with chemiluminescent substrate
CDP-STAR (New England BioLabs). Filters were overlaid with film and devel-
oped.
Cell cultures. Vero E6 and MA104 cells were maintained in Eagle’s minimal
essential medium containing 10% fetal calf serum, kanamycin (0.25 g/ml), and
gentamicin (0.05 g/ml). Caco-2 cells were maintained in Dulbecco’s high-glu-
cose minimal essential medium containing 20% fetal calf serum, 0.1 M nones-
sential amino acids, kanamycin (0.25 g/ml), and gentamicin (0.05 g/ml). Ur-
bani and icSARS-CoV wild-type viruses and SARS-CoV GFP were propagated
and plaque isolated on Vero E6 cells. All virus work was performed in a bio-
logical safety cabinet in a biosafety level 3 laboratory containing redundant
exhaust fans; personnel were dressed in Tyvek suits, full hoods, and powered
air-purifying respirators with high-efficiency particulate air (HEPA) and organic
vapor filters.
Human nasal and tracheobronchial epithelial cells were obtained from airway
specimens resected from patients undergoing elective surgery under UNC Insti-
tutional Review Board-approved protocols by the UNC Cystic Fibrosis Center
Tissue Culture Core. Briefly, primary cells were expanded on plastic to generate
passage 1 cells and plated at a density of 250,000 cells per well on permeable
Transwell-Col (12-mm-diameter) supports (14, 43). HAE cultures were gener-
ated by provision of an air-liquid interface for 4 to 6 weeks to form well-
differentiated, polarized cultures that resemble in vivo pseudostratified muco-
ciliary epithelium (43). Cultures of airway epithelial cells derived from alveolar
regions of the human lung were obtained by plating primary human alveolar cells
(ScienCell Research Labs, CA) or A549 cells on Transwell-Col supports and
maintained for 5 days before viral inoculation in manufacturer-supplied medium
or Dulbecco’s high-glucose minimal essential medium, respectively.
Apical or basolateral virus inoculations were performed with 200 l of virus
stocks applied to the apical or basolateral surfaces of HAE, respectively. Prior to
apical inoculation, the apical surfaces of HAE were rinsed three times over 30
min with phosphate-buffered saline (PBS) at 37°C. Basolateral inoculations were
performed by inverting the Transwell-Col insert prior to addition of virus. Fol-
lowing a 2-h viral inoculation at 37°C, all inocula were removed and HAE were
maintained with an air-liquid interface for the remainder of the experiment. To
generate growth curves at specific times after viral inoculation, 120 l of tissue
culture medium was applied to the apical surface of HAE and collected after a
10-min incubation at 37°C. Basolateral samples were collected by removing 120
l of basolateral medium at each time point. All samples were stored at 80°C
until assayed for plaque formation on Vero E6 cells as described above.
Mouse, hamster, and rhesus monkey airway epithelial cell cultures. Briefly,
mouse and hamster tracheas were excised between the larynx and bronchial
branches by use of a sterile technique. Epithelial cells were isolated following
overnight incubation with pronase and subsequent incubation with pancreatic
DNase I. Following a short incubation to allow for fibroblast adherence, mouse
epithelial cells were plated in TEC Plus (TEC basic medium plus 10 g/ml
insulin, 5 g/ml transferrin, 0.1 g/ml cholera toxin, 25 ng/ml epidermal growth
factor [Becton Dickinson, Bedford, MA], 30 g/ml bovine pituitary extract, 5%
fetal bovine serum, and freshly added 0.01 M retinoic acid) on rat-tail-collagen-
coated Transwell-Clear membranes at various cell densities ranging from 100,000
to 250,000 cells per well. Following the fibroblast adherence step, hamster cells
were plated on Transwell-Col membranes at 100,000 to 200,000 cells per well.
Once a confluent monolayer was established, apical medium was removed and
cells were maintained at the air-liquid interface. From this point on, cells were
grown in TEC/NS (NuSerum; Becton Dickinson) (47). Basolateral medium was
refreshed every 2 days, and cultures were washed with PBS on the apical surface
once per week. Rhesus monkey tracheobronchial specimens were a gift from
Rebecca Grant (Nonhuman Primate Research Program, UPENN), and ciliated
airway cultures were established exactly as described above for the human airway
cultures.
Microscopy. For detection of viral structural antigens, antisera against SARS-
CoV structural S and N proteins were generated by inoculation of mice with
Venezuelan equine encephalitis virus (VEE) replicon particles (VRPs) express-
ing the individual consensus sequences of S and N. Briefly, S and N were cloned
into the pVR21 VEE replicon vector by overlapping-extension PCR with SARS-
CoV- and VEE-specific primer pairs and PCR conditions previously described
for the insertion of norovirus capsid genes (3). VRPs carrying the SARS-CoV S
and N ORFs were produced as previously described (20, 21). The VRPs were
inoculated into the footpads of 4-week-old mice and boosted at 30 days postin-
fection, prior to the harvesting of antiserum (20, 21). Mouse anti-S and -N titers
exceeded 1:10,000.
For detection of SARS-CoV antigens in HAE, cultures inoculated with Ur-
bani, icSARS-CoV, and SARS-CoV GFP (5  106 PFU/ml) were fixed in 4%
paraformaldehyde (PFA) for 24 h, transferred to 70% ethanol, and prepared as
paraffin-embedded histological sections by the UNC Cystic Fibrosis Center Mor-
phology and Morphometrics Core. After deparaffinization, histological sections
were incubated for 1 h in PBS containing 3% bovine serum albumin (BSA).
Primary antibodies were applied at a 1:100 dilution in PBS with 1% BSA over-
night and detected with anti-mouse antibody conjugated to Texas Red (Jackson
ImmunoResearch). For detection of hACE2 in human airway samples and HAE,
frozen sections of fresh nasal and tracheobronchial airways or HAE were fixed in
ice-cold methanol, blocked in 3% BSA-PBS, and then probed overnight with
goat polyclonal anti-hACE2 (AB933; R&D Systems) or an irrelevant antibody
control (goat anti-biotin) at a 1:100 dilution, followed by a donkey anti-goat
immunoglobulin G conjugated to Texas Red. Immunofluorescence was visual-
ized with a Leica Leitz DMIRB inverted fluorescence microscope equipped with
a cooled color charge-coupled digital camera (MicroPublisher; QImaging). A
tricolor filter cube set (GFP/Texas Red/DAPI [4,6-diamidino-2-phenylindole])
was used to show the morphology of the tissue section (by combining low-level
autofluorescence levels across the three filters), thus aiding determination of
fluorescent antibody localization to specific regions of the cells. Visualization of
virus with transmission scanning electron microscopy was performed by using
standard techniques with HAE inoculated with Urbani, icSARS-CoV, or SARS-
CoV GFP fixed at 48 h postinfection in 2% PFA-2% glutaraldehyde. Represen-
tative images infected with Urbani are shown.
Antibody blockade. To determine whether SARS-CoV infection could be
blocked with anti-hACE2, the apical surfaces of HAE were rinsed and 300 l of
a 1:10 dilution of monoclonal anti-hACE2 (MAB933; R&D Systems), polyclonal
anti-hACE2 (AB933; R&D Systems), or control antibody (anti-MUC1, clone
b27.29, a gift from Fujirebio Diagnostics, Inc.) (8) was applied to the apical
surface of HAE; 2 h later, antisera were removed from the apical surface.
SARS-CoV GFP (200 l; 5  106 PFU/ml) or PIV3 expressing GFP (107
PFU/ml) was then inoculated onto the apical surface and incubated for an
additional 2 h at 37°C. Viral inocula were then removed, and 30 l of the original
diluted antiserum was returned to the apical surface of HAE. As described above
for SARS-CoV GFP, apical washes were collected at 2, 6, 12, 22, and 36 h
postinfection to assess viral growth titers by plaque assay in Vero E6 cells. At
36 h postinfection, HAE were fixed (4% PFA) prior to quantitative assessment
of GFP expression performed with image-processing tool kit plug-ins for Pho-
toshop (ISBN 1-928808-00-X; John Russ).
RESULTS
Localization of hACE2 in human airway epithelia ex vivo
and in vitro. To determine if upper (nasal) and lower (tracheo-
bronchial) regions of human conducting airway epithelia ex-
pressed the SARS-CoV receptor, hACE2, histological sections
of freshly excised human airway tissue isolated from the nasal
and tracheobronchial regions were probed with polyclonal an-
tisera specific for hACE2 and immunoreactivity was assessed
by fluorescent secondary antibody. In tissue sections of nasal
(Fig. 1A and B) and tracheobronchial (Fig. 1C and D) regions,
hACE2 immunoreactivity was detected on the luminal surface
of the airway epithelia and was specifically localized to the
apical membranes of ciliated airway epithelial cells. Although
hACE2 was present at the apical surface of ciliated cells, it was
not detected in association with the cilial shafts per se but
rather was localized to regions corresponding to the apical
membranes of these cells (Fig. 1A and C). To determine
whether human ciliated airway epithelium cultures showed a
similar distribution of hACE2 in vitro, we also probed histo-
logical sections of HAE with hACE2 antibodies. hACE2 was
detected on the luminal surface of HAE and localized specif-
ically to the apical surface of ciliated cells (Fig. 1E and F), thus
recapitulating the findings for hACE2 localization in ex vivo
tissue. Given the previously reported data that hACE2 serves
as a receptor for SARS-CoV (30), the localization of hACE2
to the luminal membrane of ciliated cells suggests that SARS-
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CoV that enters the lumen of the human airway may utilize
ciliated cells as a primary cell target for infection. Since
hACE2 was localized to ciliated cells in vitro and ex vivo and
we have previously reported that ciliated HAE are infected by
several common human respiratory viruses, we predicted that
the HAE model would serve as an excellent system to study
characteristics of SARS-CoV infection, replication, spread,
and pathogenesis (73, 74).
Construction and characterization of the SARS-CoV GFP
virus construct. To directly observe the extent and kinetics of
SARS-CoV infection of HAE in real time, we constructed
recombinant, GFP-expressing SARS-CoV (SARS-CoV GFP)
to monitor infection. A schematic of the design of SARS-CoV
GFP and the SARS-CoV cloning strategy are shown in Fig. 2A
and B, respectively. To generate recombinant SARS-CoV
GFP, the F plasmid was mutated to replace ORF7a/7b with the
GFP cDNA, using the type IIS restriction enzyme approach
described previously (71). The mutated F fragment was con-
firmed by sequence analysis and amplified in Escherichia coli
with wild-type fragments A through E. Fragments were then
isolated by digestion with the appropriate restriction enzyme,
purified, and ligated into a genomic-length cDNA. The full-
length cDNA was transcribed, and genomic-length RNA was
coelectroporated with SARS-CoV N transcripts into Vero E6
cells. GFP-positive cells were detected within 24 h of transfec-
tion, and clarified supernatant from transfected cells when
passed to fresh Vero E6 monolayers resulted in viral cytopathic
effect and green fluorescent cells. The deletion of ORF7a/7b
did not obviously affect efficient SARS-CoV replication in tis-
sue culture, which is similar to observations with transmissible
gastroenteritis virus and mouse hepatitis virus when GFP was
inserted into accessory ORFs of these viruses (1, 9, 12, 54).
Prior to further evaluation, five individual plaques of SARS-
CoV GFP were isolated, amplified, and monitored for GFP
fluorescence in addition to sequence confirmation of the mu-
tation. All plaques contained GFP and had appropriate se-
quence mutations.
To determine if levels of replicated subgenomic RNA spe-
cies from the SARS-CoV GFP construct were similar to those
of wild-type SARS-CoV, total RNA was isolated from Urbani-,
FIG. 1. Localization of hACE2 on the apical surface of human airway epithelium ex vivo and in vitro. Representative histological frozen
sections of freshly excised human nasal (A and B) or human tracheobronchial (C and D) airway tissues or HAE (E and F) were probed with either
goat polyclonal anti-hACE (A, C, and E) or goat polyclonal anti-biotin (B and F) as a species-specific negative-control antibody. Bound primary
antibody was visualized using donkey anti-goat secondary antibody conjugated to Texas Red. Immunofluorescence indicative of hACE (red) was
detected in nasal and tracheobronchial tissue as well as HAE and was localized specifically to the apical membrane of ciliated cells (arrows).
Nonciliated cell types present in the airway tissue or HAE were negative for hACE immunolocalization (arrowheads). Panel D shows Alcian blue
(pH 2.5)- periodic acid-Schiff staining of human tracheobronchial airway tissue to highlight nonciliated cells (mucin-containing cells) present in the
epithelium. Representative images are from specimens obtained from three different patients. Bar, 30 m.
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icSARS-CoV-, and SARS-CoV GFP-infected cells. Oligotex
mRNA columns were used to enrich for poly(A)-containing
mRNAs which were run on agarose gels and assayed by a
leader-containing N-gene-specific probe (Fig. 2C). The total
numbers of RNA species and relative levels of transcription
were similar for Urbani, icSARS-CoV, and SARS-CoV GFP,
suggesting that there was no transcriptional defect associated
with deletion of ORF7a/7b. While the relative levels of sub-
genomic RNA were similar for all three viruses, the replace-
ment of ORF7a/7b caused the expected shifts in size of sub-
genomic RNAs 2 through 7, demonstrating that the removal of
ORF7a/7b was not detrimental to virus replication in vitro and
that the GFP insert was stable. RNA isolated from mock-
infected samples had no detectable leader-containing mRNA
species.
To evaluate the growth kinetics of SARS-CoV GFP, growth
curves were generated for three different mammalian epithe-
lial cell lines. For Vero E6 cells, Urbani and SARS-CoV GFP
grew to titers of2 107 PFU/ml, while icSARS-CoV peaked
at 1.0  107 PFU/ml (data not shown). For MA104 cells, all
three viruses grew to titers of 3  107 to 5  107 PFU/ml by
32 h postinfection, whereas for Caco-2 cells, titers of all three
viruses were reduced by approximately 1 log compared to titers
of viruses with MA104 cells. Efficient replication of SARS-
CoV GFP and wild-type virus was noted at both high and low
multiplicities of infection (data not shown). Overall, replacing
ORF7a/7b with GFP in SARS-CoV GFP was not detrimental
to virus replication in any of the three cell lines evaluated, thus
providing a fluorescent marker of virus infection with replica-
tion at wild-type virus levels.
FIG. 3. SARS-CoV GFP infects human airway epithelial cells de-
rived from nasal and tracheobronchial epithelia but not alveolar epi-
thelium. The apical surfaces of HAE derived from nasal (A) or tra-
cheobronchial (B) airway tissues or alveolar regions of the human lung
(C and D) were inoculated with SARS-CoV GFP (A, B, and C) or
human PIV3 expressing GFP (D), and 48 h later, GFP-positive cells
were assessed with fluorescent microscopy. Although nasal and tra-
cheobronchial HAE were efficiently infected by SARS-CoV GFP, al-
veolar-derived cells were poorly infected by SARS-CoV (C) but effi-
ciently infected by PIV3 (D). Similar data were obtained for alveolar
cultures derived from A549 cells.
FIG. 2. Schematics of SARS-CoV GFP construct and SARS-CoV
infectious cloning strategy and subgenomic RNA transcription levels.
(A) Schematic representation of the SARS-CoV genome, with all
defined ORFs indicated by rectangles. Viral leader sequences are
indicated by dark gray squares at the 5 end of the genome (arrow-
head) and between each ORF. The arrow indicates the 5 viral leader
transcription regulatory sequence (TRS). (B) Schematic representa-
tion of the SARS-CoV infectious cloning strategy and the mutations to
engineer the GFP into ORFs7a/7b. The fragments of the genome are
indicated by rectangles with the ORFs in each, as shown in panel A.
The ORFs of the F clone have been expanded to indicate the location
of GFP within the SARS-CoV GFP infectious-clone construct. (C) To
determine levels of viral RNA synthesis from wild-type and SARS-
CoV GFP viruses, total RNA was isolated from infected cells at 12 h
postinfection and probed with a nucleocapsid-specific leader-contain-
ing probe. mRNAs 2 through 9 were detected for all samples, demon-
strating that deletion of ORF7a/7b allowed the synthesis of all sub-
genomic RNA species. The filled arrowhead indicates wild-type
mRNA 7, and the open arrowhead indicates the increased size of
mRNA 7 associated with ORF7a/b excision and replacement with
GFP. Samples are indicated across the top of the gel, and the individ-
ual RNA species are specified to the left and right of the image.
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SARS-CoV infection of human airway epithelia. To deter-
mine whether SARS-CoV GFP could infect human airway
epithelial cells derived from different regions of the lung, we
prepared cultures of nasal and tracheobronchial ciliated epi-
thelium as models of proximal airway epithelium and cultures
of alveolar epithelium as models of distal lung regions. As a
model of virus entry into the lumen of the airway, we inocu-
lated the apical surfaces of these cultures with SARS-CoV
GFP (5  106 PFU/ml) and assessed GFP fluorescence 48 h
later. As shown in Fig. 3, HAE derived from nasal and tra-
cheobronchial regions were efficiently infected by SARS-CoV
GFP, with a large proportion of the cells expressing the marker
transgene (Fig. 3A and B). In contrast, primary epithelial cells
derived from alveolar regions of the human lung were poorly
infected, if at all, by SARS-CoV GFP, with little evidence for
GFP expression (Fig. 3C). Use of antisera against S also failed
to detect SARS-CoV GFP or icSARS-CoV infection of these
cells (data not shown). To determine if these cells were sus-
ceptible to infection with other common respiratory viruses in
parallel, we also inoculated alveolar cultures with recombinant
PIV3 or RSV expressing GFP (106 PFU). Both PIV3 (Fig. 3D)
and RSV (not shown) efficiently infected primary cultures of
alveolar cells. Similar data were obtained for SARS-CoV GFP,
PIV3, and RSV inoculations of the alveolar cell line A549 (not
shown). These data demonstrate that the human airway epi-
thelium that lines the conducting airways of the lung was sus-
ceptible to infection by SARS-CoV GFP and that, in our
hands, cells derived from the distal alveolar regions were
poorly infected by SARS-CoV GFP.
To determine whether SARS-CoV could spread throughout
cells of HAE, SARS-CoV GFP was inoculated onto the apical
or basolateral surface of cultures for 2 h at 37°C (5  106
PFU/ml) and levels of GFP fluorescence were monitored from
19 to 140 h postinfection. Inoculation of SARS-CoV GFP onto
the apical surface of the HAE resulted in detectable levels of
GFP as early as 19 h postinfection (Fig. 4A), with peak viral
replication occurring between 68 (Fig. 4E) and 90 (Fig. 4G) h
postinfection and GFP still detected at 140 h postinfection
FIG. 4. Infection and spread of SARS-CoV GFP infection in HAE
over time after apical or basolateral inoculation. HAE were inoculated
via the apical (A, C, E, G, and I) or basolateral (B, D, F, and H)
compartments with SARS-CoV GFP and GFP-positive cells and as-
sessed over time (1 to 5 days postinfection). HAE inoculated with
vehicle alone showed no GFP-positive cells (J). Apical inoculation
resulted in significant numbers of GFP-positive cells at 40 h postinfec-
tion (C), with efficient spread of infection by 90 h postinfection (G). In
contrast, basolateral inoculation resulted in a low proportion of cells
positive for GFP only at 68 h postinfection (F). These images are
representative of duplicate cultures from at least three different pa-
tient sets. Original magnification, 10. (K) Apical inoculation of HAE
with Urbani or icSARS-CoV was performed, and apical washes and
basolateral media were harvested at the indicated time points postin-
fection. Collected samples were serially diluted, and titers were deter-
mined by plaque assay with Vero E6 cells. Titers are expressed as
PFU/ml. Both Urbani and icSARS-CoV replicated to high titers in the
apical compartment of HAE within 24 h, whereas progeny virions were
detected in the basolateral compartment at later time points and to
lower levels. All infections were performed in duplicate. Filled circles,
Urbani apical; open circles, Urbani basolateral; filled squares, icSARS-
CoV apical; open squares, icSARS-CoV basolateral.
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(Fig. 4I). In contrast, inoculation of the basolateral membrane
of HAE with SARS-CoV GFP resulted in only a low number
of fluorescent cells at 68 h postinfection, indicating that this
was not the most productive route for SARS-CoV infection of
HAE (Fig. 4B, D, F, and H). These data show that HAE are
efficiently infected by SARS-CoV via the apical surface
whereas basolateral surface inoculation is comparatively resis-
tant to infection. Interestingly, by 140 h significant loss of GFP
fluorescence was observed, an effect most likely related to the
loss of SARS-CoV-infected cells (see below).
To determine whether shedding of progeny SARS-CoV
from HAE was polarized, apical washes and basolateral media
were sampled at 2, 9, 21, 31, and 48 h postinfection with Urbani
or icSARS-CoV and viral titers were assessed by plaque assay
with Vero E6 cells (Fig. 4K). The peak titers of Urbani and
icSARS-CoV shed from the apical surface approximated 107
PFU/ml, demonstrating a high level of replication similar to
that observed with Vero E6 cell monolayers (Fig. 4K). In
contrast, viral titers in the basolateral compartments were low
for both Urbani and icSARS-CoV, with peak titers of 104
PFU/ml (Fig. 4K). Following apical inoculation, no infectious
virus was detected until after 20 h postinfection in basolateral
media. Since viral titers from the apical compartment of HAE
were 2 to 3 logs higher than those detected from basolateral
compartments for both viruses and the numbers of GFP-pos-
itive cells after apical and basolateral inoculation with SARS-
CoV GFP also correlated with the different magnitudes of viral
titers from the two compartments, these data suggest that
within the first 48 h of infection SARS-CoV predominately
sheds from the apical surface of HAE. An apical route of
infection, shedding, and reinfection with progeny virus corre-
lates with the apical localization of hACE2 on airway tissues
(Fig. 1A, C, and E). Since SARS-CoV replicates to titers sim-
ilar to those in permissive cell lines, these data indicate that
SARS-CoV replicates well in HAE, providing a new model of
the human lung epithelium for the study of SARS-CoV repli-
cation and pathogenesis.
Identification of SARS-CoV-infected cells in HAE. Having
demonstrated that SARS-CoV can productively infect HAE
after apical inoculation, we next determined whether SARS-
CoV targeted specific airway epithelial cell types. Since hACE2
was detected exclusively on the apical surfaces of ciliated cells
in ex vivo human airway tissue and HAE in vitro, we predicted
that ciliated cells would be infected by SARS-CoV. Histolog-
ical sections from HAE infected with Urbani, icSARS-CoV, or
SARS-CoV GFP for 48 h were probed with mouse polyclonal
antisera directed against SARS-CoV structural proteins S or
N, and localization was assessed by standard immunofluores-
cence techniques. For all viruses, S (Fig. 5A and B) and N (Fig.
5C) immunoreactivity was detected in ciliated cells, correlating
with the localization of hACE2 to ciliated cell types (Fig. 1E).
In experiments performed with HAE derived from four differ-
ent patients, evidence of S immunoreactivity was detected only
in cells that morphologically resembled ciliated cells. In all
cases, no S or N immunoreactivity was detected in nonciliated
cells. Interestingly, immunoreactivity against S was most abun-
dant at the apical surface of ciliated cells in regions corre-
sponding to the microvillus structures but low levels of S im-
munoreactivity were also detected within the cytoplasm of
ciliated cells (Fig. 5B). In contrast, immunoreactivity to N
protein was detected throughout the cytoplasm of SARS-CoV-
infected ciliated cells, a localization indicative of the associa-
tion of N with sites of CoV replication and assembly (Fig. 5C).
Primary cultures of HAE that were confluent and polarized
but not differentiated (i.e., cultures maintained at air-liquid
interface for 5 days) were not infected by SARS-CoV as
determined by GFP or S immunolocalization (data not shown).
To confirm that ciliated cells could be infected by SARS-
CoV, we performed transmission electron microscopy on fixed
FIG. 5. SARS-CoV infects ciliated cells after apical inoculation of
HAE. Representative histological sections of HAE 48 h postinfection
with icSARS-CoV (A, B, and C) probed with mouse anti-S (A and B),
mouse anti-N (C), or a mouse irrelevant anti-hemagglutinin (D) and
visualized with anti-mouse secondary antibodies conjugated to Texas
Red (red). Detection of S or N immunoreactivity was localized spe-
cifically to the ciliated cells of HAE (arrows), indicating that SARS-
CoV infects this cell type after apical inoculation. No immunoreactivity
was observed for nonciliated cell types (arrowheads). Images were
obtained with a tricolor fluorescent filter to define the morphology of
the tissue (gray/blue), with original magnifications of 40 (A) and
100 (B, C, and D).
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FIG. 6. Ultrastructural localization of SARS-CoV in HAE. Representative transmission electron microscopic photomicrographs of HAE infected
with Urbani SARS-CoV. (A) HAE inoculated with vehicle alone, demonstrating the typical morphological features of the apical surfaces of ciliated cells
with prominent cilia and microvilli. (B to E) HAE inoculated with Urbani SARS-CoV 48 h before fixation and showing the presence of large numbers
of virus particles in vesicles inside ciliated cells (B and E) and on the surface of ciliated cells (B, D, and E) or shed into pericilial regions (C). Large
quantities of virions were noted on the surface of ciliated cells, where ciliated cells were identified by cilial basal bodies (E). (F to H) To confirm that
the observed virions were SARS-CoV, immuno-EM was performed using polyclonal mouse antisera against S with secondary antibodies conjugated to
12-nm colloidal gold (F). SARS-CoV infection resulted in extrusion and shedding of infected ciliated cells into the airway surface microenvironment (G
and H). Similar observations were seen with HAE infected with icSARS-CoV and SARS-CoV GFP. Scale bars are shown for each panel. Filled
arrowheads, cilia; filled arrows, microvilli; open arrowheads, virions; thin-tailed arrow in panel F, immuno-EM colloidal gold.
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HAE 48 h postinfection with Urbani, icSARS-CoV, or SARS-
CoV GFP. HAE inoculated with SARS-CoV (representative
pictures are of Urbani infection) showed ciliated cells contain-
ing classic coronavirus cytoplasmic vesicles filled with viral
particles (Fig. 6B, G, and H). In addition, large numbers of
viral particles were seen within the spaces between the mi-
crovilli/cilia shafts as well as in the airway surface microenvi-
ronment that surrounds the apical surface of ciliated cells,
suggesting mechanisms for the release of large quantities of
SARS-CoV into the lumen of the conducting airway during
viral replication (Fig. 6C, D, E, and F). Immuno-electron mi-
croscopy (EM) detecting S confirmed that particles detected in
the airway surface microenvironment were indeed SARS-CoV
virions (Fig. 6F). Therefore, SARS-CoV entry, replication, and
release occur in hACE2-positive ciliated cells of HAE.
SARS-CoV infection of ciliated epithelial cells is hACE2
dependent. To determine if SARS-CoV infects ciliated cells via
an interaction with hACE2, we utilized antibody blockade ex-
periments with antisera directed against hACE2, a method
that has previously been shown to block the interaction of
SARS-CoV with hACE2 in Vero E6 cells (30). HAE were
preincubated with polyclonal or monoclonal antisera directed
against hACE2 (R&D Systems) or a control antibody that
binds to the apical surface of HAE (anti-tethered mucin
MUC1, clone b27.29) for 2 h prior to inoculation with SARS-
CoV GFP (5  106 PFU/ml). Quantitative analyses of the
number of GFP-positive cells 36 h postinfection revealed that
HAE pretreated with polyclonal hACE2 antibody alone ab-
lated the levels of GFP-positive cells compared to controls
(Fig. 7A). However, no inhibition of SARS-CoV GFP infec-
tion was observed with the monoclonal hACE2, indicating that
the epitope recognized by the monoclonal hACE2 does not
sterically inhibit the interaction of this molecule with SARS-
CoV. No inhibition of infection was observed with a control
antibody that binds to a highly abundant epitope on the apical
surface of HAE (MUC1) (55). None of these antibodies sig-
nificantly affected infection of ciliated cells by a recombinant
PIV3 expressing GFP, indicating that the steric hindrance of
hACE2 was specific to SARS-CoV infection. To confirm that
the addition of polyclonal hACE2 antisera reduced not only
the number of GFP-positive cells but also the replication of
viral progeny, we assessed the growth kinetics of SARS-CoV
GFP generated from the apical surface of infected HAE in the
absence and presence of the antibodies described above. Api-
cal-surface sampling was performed from 2 to 36 h postinfec-
tion, and titers of virus were determined by plaque assay with
Vero E6 cells. In the absence of antisera or in the presence of
control antisera, SARS-CoV GFP replicated to titers of 107
PFU/ml (Fig. 7B), similar to titers detected with the wild-type
Urbani and icSARS-CoV strains (Fig. 4K). In contrast, in the
presence of hACE2 polyclonal antisera, viral titers were re-
duced by at least 2 logs. Monoclonal antisera against hACE2
again failed to effect viral growth, confirming that this antibody
was not sufficient to block SARS-CoV entry into ciliated cells.
Therefore, both assessment of SARS-CoV infection by analy-
ses of GFP-positive cells and viral growth kinetics suggest that
hACE2 is the predominant receptor used by SARS-CoV for
infection of ciliated cells in HAE.
Consequences of SARS-CoV infection on ciliated epithelial
cell morphology. To determine the consequences of ciliated
cell infection by SARS-CoV over time, histological sections
derived from HAE infected with SARS-CoV GFP for 20 to
140 h were probed with anti-S antisera. GFP was used to assess
infection in real time before HAE were fixed and sectioned.
Immunoreactivity against S in ciliated cells could be detected
as early as 24 h postinfection (data not shown) and by 48 h
postinfection was robustly located at the apical surface of cil-
iated cells (Fig. 8A). By 72 h (Fig. 8B), S immunoreactivity
FIG. 7. hACE2 is the primary receptor for SARS-CoV entry into
HAE. (A) HAE were pretreated with polyclonal or monoclonal anti-
sera directed against hACE2 (pACE2 and mACE2, respectively) or an
anti-MUC1 negative-control antibody prior to inoculation with SARS-
CoV GFP (black bar) or PIV3 expressing GFP (gray bar). Thirty-six
hours postinfection, the numbers of GFP-positive cells for each anti-
serum treatment were assessed, demonstrating that pACE2 could ab-
late SARS-CoV infection of HAE but that mACE2 or MUC1 antisera
had no effect on SARS-CoV infection. None of the antiserum treat-
ments significantly affected PIV3 infection of HAE. (B) To assess
effects of pretreatment of HAE with receptor-specific antisera on the
growth kinetics of SARS-CoV infection, apical washes at the indicated
time points were collected and results were determined by plaque
assay with VeroE6 cells. Results represent data obtained from HAE
derived from two different patients. Titers are expressed as PFU/ml.
Filled squares, polyclonal hACE2 only; open squares, polyclonal and
monoclonal hACE2; filled circles, monoclonal hACE2 only; filled tri-
angles, MUC1; filled diamonds, no antiserum.
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remained at the apical surfaces of ciliated cells but was also
present on the basolateral surfaces of the infected cells. Late in
infection (96 and 120 h), S-positive ciliated cells appeared to
extrude from the epithelium onto the luminal surface of HAE
(Fig. 8C and D). Extruded ciliated cells often showed S immuno-
reactivity around the entire periphery of the cells (Fig. 8D). These
data demonstrate that SARS-CoV infection of ciliated cells in
HAE resulted in shedding of the infected ciliated cells into the
airway lumen. Furthermore, the presence of SARS-CoV immu-
noreactivity at the basolateral surfaces at later time points postin-
fection suggests that SARS-CoV would also enter the basolateral
compartments of HAE, as was shown in Fig. 4K.
Susceptibility of animal airway epithelial cells to SARS-CoV
infection. SARS-CoV is an emerging pathogen whose natural
host range has not been clearly established. However, in vivo
studies have shown that SARS-CoV can replicate in the
mouse, hamster, cat, civet cat, ferret, and nonhuman primate
lung, and murine and hamster models for the study of SARS-
CoV pathogenesis and vaccine production have been devel-
oped (34, 41, 44, 45). The civet cat likely represents an impor-
tant reservoir for transmission to humans (17). Airway
epithelial cell cultures similar to the human model described
here but derived from susceptible species may provide an im-
portant comparative model to determine the mechanisms of
pathogenesis and replication efficiency in alternative hosts. To-
wards this goal, we have successfully generated ciliated airway
epithelium models derived from tracheobronchial airway epi-
thelia of C57BL/6 mice (Fig. 9A), golden Syrian hamsters
(HmAE) (Fig. 9B), and rhesus macaques (Fig. 9C). Inocula-
tion of the apical surfaces of these cultures with SARS-CoV
GFP indicated that SARS-CoV GFP replicated to some extent
in ciliated cells of airway epithelia of rhesus macaques (Fig.
9F), to a lesser extent in HmAE (Fig. 9E), and to a much lesser
extent in airway epithelia of C57BL/6 mice (Fig. 9D). Again,
although fewer cells than HAE were infected, ciliated epithe-
lial cells were the predominant cell targets for SARS-CoV
GFP infection (data not shown). The growth of virus and the
percentages of infected cells were greatly reduced compared
with infection rates and viral titers achieved with HAE, as
evidenced by titers of 106 PFU/ml in HmAE (e.g., SARS-
CoV GFP only reached 1.4  106 PFU/ml after 72 h postin-
fection); however, a rough parallel was noted with infection of
ciliated cells derived from human  nonhuman primate 
hamstermouse, roughly correlating to the severity of disease
noted for each species (34, 37, 45, 56, 65). Clearly, HAE are
the most robust airway model for studying SARS-CoV repli-
cation and pathogenesis in the lung.
DISCUSSION
The human conducting airway epithelia of the nasal and
tracheobronchial regions consist of a pseudostratified muco-
ciliary epithelium with predominant ciliated cells interspersed
with mucus-secreting goblet cells overlaying a basal cell layer.
The predominant cells of the cuboidal epithelium of the hu-
man distal bronchiolar airways are also ciliated cells. The air-
way epithelium is often the first tissue encountered by intralu-
minal pathogens, and ciliated cells are major targets for
common respiratory viruses, such as RSV, PIV3, and influenza
(36, 73, 74). In this study, in vitro models of human airway
epithelia derived from nasal and tracheobronchial regions
were susceptible to SARS-CoV infection after luminal inocu-
lation of virus, and the cell types targeted preferentially by
SARS-CoV were ciliated epithelial cells. In our hands, nonpo-
larized or polarized but not differentiated human airway epi-
thelial cells derived from nasal or tracheobronchial airway
FIG. 8. Morphological consequences of SARS-CoV infection of
ciliated cells. Representative histological sections of HAE inoculated
with SARS-CoV GFP and probed with mouse anti-S conjugated to
Texas Red at 48, 96, 120, and 144 h postinfection (A to D). S local-
ization (red) was restricted to the apical surface of ciliated cells by 48 h
(A), but by 96 h postinfection, in some cases S immunoreactivity was
detected around the periphery of the ciliated cells (B) (arrow), sug-
gesting basolateral shedding of SARS-CoV. By 120 h postinfection,
infected ciliated cells began to extrude from the epithelium (C) (ar-
row), and by 144 h postinfection, infected ciliated cells or components
thereof were shed into the luminal compartment of HAE (D) (arrow).
Note that the shed ciliated cell was positive for S immunoreactivity
around the periphery of the cell, suggesting that virus was being shed
from these regions. Bar, 5 m. Images were obtained with a tricolor
fluorescent filter to define the morphology of the tissue (gray/blue),
with an original magnification at 100.
FIG. 9. SARS-CoV GFP infection of mouse, hamster, and rhesus
monkey airway epithelial cell cultures. Ciliated airway epithelial cell
cultures were derived from mice (A and D), hamsters (B and E), and
rhesus monkeys (C and F) and inoculated via the apical surface with
SARS-CoV GFP (106 PFU). Hematoxylin and eosin-stained histolog-
ical sections are shown for each species (A, B, and C), and GFP
fluorescent images were recorded 48 h postinfection (D, E, and F).
Original magnifications were 40 (A, B, and C) and 10 (D, E, and
F). Bar, 5 m (A, B, and C).
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specimens were not infected by SARS-CoV (data not shown).
Previously, we showed that RSV and PIV3 also targeted cili-
ated cells and that HAE required ciliated cell differentiation
for infection, since polarized but not differentiated HAE were
not infected by these viruses (73, 74). Furthermore, we showed
that the numbers of cells infected by RSV and PIV3 directly
correlated with ciliogenesis, indicating that ciliated cell differ-
entiation was necessary for infection (73, 74). Although we
show that SARS-CoV targets ciliated cells in HAE, we cannot
rule out the possibility that SARS-CoV also infects nonciliated
airway epithelial cells in vivo. A variety of nonciliated cell types
are present in HAE, with some cells possessing morphology
and markers indicative for mucin-containing cells and others
with morphology that resembles precursors of ciliated cells.
Since we do not fully appreciate the range of nonciliated cells
in HAE, it is possible that these cells do not represent the
nonciliated cell types found in the airway epithelium in vivo.
Rather, it is our intention in this paper to describe the ciliated
cell tropism for SARS-CoV in the HAE model. A recent re-
port shows that Calu-3 cells are susceptible to SARS-CoV
infection (61) and that although these cells are derived from
human lung epithelial cells and polarize when grown on semi-
permeable supports, these cells do not recapitulate the differ-
entiated status of the airway epithelium in vivo as do the HAE
reported in the current study. The fact that Calu-3 cells do not
possess differentiation markers of the human airway epithe-
lium (e.g., cilia) and are only moderately infected by SARS-
CoV suggests that the HAE model may be more representative
of SARS-CoV infection of the human airways.
Importantly, hACE2, a receptor for SARS-CoV, was local-
ized to the ciliated cells of human nasal and tracheobronchial
airway epithelia and to ciliated cells of HAE, reflecting the
ciliated cell targeting capacity of SARS-CoV. Importantly, an-
tibodies directed against hACE2 efficiently inhibit infection,
replication, and spread of SARS-CoV in HAE (Fig. 7), similar
to results reported with Vero E6 and 293 cells expressing
hACE2 (30, 57), suggesting that hACE2 functions as the prin-
ciple receptor for SARS-CoV infection of the conducting air-
way epithelium (Fig. 1 and 7). These data are in stark contrast
to results obtained by Hamming et al. (19), where hACE2
expression was detected in the alveolar regions and the basal
layer of the nonkeratinized squamous epithelium of the upper
respiratory tract (18). Our findings of hACE2 expression and
productive SARS-CoV infection in ciliated cells derived from
the nasal and tracheobronchial airways dispute this claim and
support the hypothesis that SARS-CoV initiates a productive
infection in human ciliated airway epithelium. It is interesting
to consider the biological significance of hACE2 expression on
the luminal surface of ciliated cells. Recently, it has been
reported that ACE2 and its role in the renin-angiotensin path-
way serve a protective function against acute lung injury (24).
In addition, SARS-CoV and an interaction with ACE2 have
been shown to interfere with this pathway, resulting in en-
hanced acute lung injury in rodent models (26). The signifi-
cance of hACE2 specifically on ciliated cell types remains to be
explored.
Interestingly, we found that SARS-CoV poorly infected our
models of airway epithelial cells derived from alveolar regions
of the human lung, a finding that has also been reported by
others (15). In comparison to Vero cells, A549 cells express
undetectable levels of hACE2 and may account for the lack of
SARS-CoV infection in these experiments. These observations
may reflect that freshly isolated human alveolar cells rapidly
lose their differentiation status (from type I or type II cells)
during culture, resulting in cell types that do not represent cell
types found in vivo. This is in contrast to HAE, for which
differentiation of airway cells to a ciliated morphology requires
6 to 8 weeks of culture. Growth of primary alveolar cells for
this length of time in vitro does not result in cultures that are
significantly different in terms of differentiation or morphology
from cultures grown for 3 to 5 days (R. J. Pickles, unpublished
observations). Therefore, such studies of alveolar regions of
the lung will require development of techniques that isolate
and preserve the differentiation status of the epithelial cells
from these regions. Alternatively, such studies may be better
suited to in vivo experimentation using relevant animal models.
Another human coronavirus, HCoV-229E, which primarily
causes a mild upper respiratory tract infection in humans, has
been shown with other models of HAE to principally target
ciliated epithelia, causing cell morphology alterations, dyski-
nesia, and cilium dysfunction (63). However, shedding of in-
fected ciliated cells, noted here during SARS-CoV infection,
was not reported following HCoV-229E infection. In contrast
to other HCoV, SARS-CoV infection is associated with severe
atypical pneumonia in adults. The major pathological findings
upon autopsy suggest SARS-CoV involvement of type II pneu-
mocytes located in the alveoli, as evidenced by detection of
viral RNAs and EM detection of virus-like particles (4, 5, 75).
Importantly, patients dying early following SARS-CoV expo-
sure show marked bronchiolar disease with respiratory epithe-
lial cell necrosis, loss of cilia, squamous metaplasia, and intra-
bronchiolar fibrin deposits. In fact, it has been suggested that
early diffuse alveolar damage as a consequence of SARS-CoV
infection may initiate in the respiratory bronchioles (13, 39).
SARS-CoV has a broad host range, replicating efficiently in
humans, primates, palm civets, raccoon dogs, hamsters, ferrets,
cats, and mice, although most-pronounced disease is noted to
occur in humans and mild persistent infections have been doc-
umented for palm civets (11, 17, 25, 34, 41, 44, 45). Signifi-
cantly reduced pathology and clinical disease are noted to
occur in ferrets, cats, hamsters, and mice (34, 41, 44, 45, 56). In
the murine model for SARS-CoV infection, replication of virus
without disease has been noted (56). Principle targets for
SARS-CoV infection are the airway epithelia of the mouse,
hamster, and ferret models (34, 44, 45, 56); however, specific
infection of ciliated cells was not described for these species.
Mechanisms of SARS-CoV cross-species transmission appear
mediated in part by the orthologues of hACE2, as SARS-CoV
derived from civet cats preferentially recognizes civet cat
ACE2 compared to rat and human ACE2 (31, 69). In mice, the
murine ACE2 orthologue functions as a receptor for SARS-
CoV entry into murine cells, but inefficient usage limits virus
replication and spread (29). As virus load is correlated with
increased pathogenesis in humans (64), it is likely that the
attenuated replication phenotypes noted for ciliated cell cul-
tures derived from different species are closely correlated with
the reduced clinical disease and pathology noted for these
alternative species. Although orthologous ACE2 may in part
explain the reduced replication phenotype in these species,
molecular epidemiologic analysis argues that SARS-CoV host
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switching was associated with positive selection in the S glyco-
protein gene, ORF1a replicase, and ORF3a (6). These data
suggest that the ORF1a replicase proteins and the group-
specific ORFs may influence replication efficiency in these
alternative species. Additional studies will be needed to iden-
tify the genetic basis restricting efficient SARS-CoV replication
in the mouse, hamster, and nonhuman primate in vitro and in
vivo models.
Respiratory viruses induce dramatically different levels of
cytopathology following infection of HAE in vitro. Influenza
virus infection of HAE results in rapid and extensive cytopa-
thology affecting ciliated and other epithelial cell types, con-
sistent with the extensive damage in the respiratory epithelium
noted with infected humans in vivo (33, 74). In contrast to the
characteristic syncytium formation noted with nonpolarized
epithelial cell lines, RSV and PIV3 exclusively target ciliated
cells in HAE but without syncytium formation (73, 74). In
addition, no shedding of progeny RSV or PIV3 from the ba-
solateral surfaces was noted, an observation supported by the
rare incidence of viremia in patients infected with these vi-
ruses. Examination of the morphology of HAE after SARS-
CoV infection demonstrated the disruption of cell-cell junc-
tions between the infected ciliated cells and the surrounding
cells by 72 h postinfection (S localization to the basolateral
region of the cell), and by 120 h postinfection, ciliated cells
positive for S were shed onto the luminal surface of HAE (Fig.
8B, C, and D). In addition, SARS-CoV was shed albeit at a low
level from the basolateral surfaces of HAE, perhaps suggesting
a mechanism by which viremia can occur with this virus, ex-
plaining subsequent virus spread to the intestine and other
organs (Fig. 4K) (51, 60). Mechanisms of viral spread to ba-
solateral compartments are unknown but most likely involve
disruption of tight junctions and diffusion rather than spread to
the basal cell layers. By EM, large numbers of virus particles
were present in ciliated cells, in budding vesicles being trans-
ported to the luminal surface, and in close proximity to the
apical surface of ciliated cells (Fig. 6B to H). Abundant num-
bers of virus particles were also trapped in cellular debris in the
luminal compartment, suggesting that cell-associated virus
might contribute to SARS-CoV spread between hosts. The
mechanism that specifies the predominant polarized release of
SARS-CoV virions is unclear, but releasing virus particles into
the lumens of airways provides a means of propagating spread
via interaction with potential viral receptors also polarized to
the luminal surface of ciliated cells, e.g., hACE2. Similar find-
ings were also reported with HCoV-229E (63). As recent re-
ports suggest that HCoV-NL63 also uses hACE2 as a receptor
for entry into cells, these data indicate that many coronaviruses
target this pathway while replicating in the lung epithelium
(23). Our data also demonstrate that SARS-CoV assembly and
release occur via budding into internal vesicles that are trans-
ported to the cell surface. Ultimately, infection results in shed-
ding of the ciliated cell, which often contains large quantities of
virus (Fig. 6D, G, and H).
EM also demonstrated extensive cytopathology and vacuol-
ization of infected cells, suggesting that considerable cell-asso-
ciated virus may be shed from infected patients (Fig. 6D, G,
and H). Future studies will determine the mechanisms mediating
the extrusion of infected ciliated cells from HAE and whether
genetic mutants of SARS-CoV produce similar results. The im-
munological consequences of ciliated cells containing virus being
shed into the airway lumen remain to be explored.
We have successfully deleted ORF7 from the SARS-CoV
genome. SARS ORF7 is divided into two ORFs, designated
ORF7a and 7b. Although no ORF7b product has been de-
scribed to date, ORF7a encodes a 122-amino-acid type 1 trans-
membrane protein and structural studies reveal a compact
seven-stranded 	 sandwich similar in fold and topology to
members of the immunoglobulin superfamily (38). ORF7a
traffics into the endoplasmic reticulum/Golgi network, the site
of coronavirus budding and assembly, suggesting a possible
role in maturation and release (38). Moreover, ORF7a of
SARS-CoV has been shown to encode a proapoptotic activity
in cells in culture (58). By use of a reverse genetic system
developed for SARS-CoV, ORF7a and ORF7b were replaced
with GFP, demonstrating a luxury function for these ORFs in
SARS-CoV GFP replication in Vero E6, MA104, and Caco-2
cells as well as HAE. As SARS-CoV GFP replicates as effi-
ciently as recombinant wild-type icSARS-CoV and Urbani
SARS-CoV in HAE and expresses equivalent amounts of sub-
genomic mRNA, ORF7 does not encode a critical function for
in vitro replication, although it might enhance in vivo patho-
genesis, as has been described with other coronavirus accessory
ORFs (9, 10, 40).
Several paradigms to explain the mechanism for spread of
SARS-CoV in the human lung have been proposed. One
model suggests that SARS-CoV infects lung dendritic cells that
transport virus to the alveolar regions, allowing for infection of
type II pneumocytes. This model is based on studies in which
dendritic cells were infected by SARS-CoV via an interaction
with overexpressed levels of DC-SIGN (35, 68). An alternative
model would predict that SARS-CoV infection and spread
could occur through some component of the respiratory epi-
thelium. Indeed, consideration of the early pathology of
SARS-CoV observed in the bronchiolar regions and the dem-
onstration that SARS-CoV replicates efficiently in ciliated cells
isolated from nasal and tracheobronchial airway regions shown
here are supportive of this latter hypothesis. Moreover, the uni-
form gradient of hACE2 expression throughout the conducting
airways of the human lung provides a suitable substrate for re-
peated cycles of virus amplification and spread throughout the
airways, ultimately spreading to some cell component of the al-
veolus regions. Since progeny SARS-CoV is predominately re-
leased onto the luminal surface of HAE, we propose that infec-
tion of ciliated cells by SARS-CoV is propagated by the
coordinated movement of cilium beat, as we have shown for the
ciliated-cell-to-ciliated-cell spread of RSV and PIV3 in HAE (73,
74). Since specific airway epithelial cell types, especially ciliated
epithelial cells, possess unique physiological and innate defense
functions in the lung, it is important to determine the airway cell
tropism of SARS-CoV in the human lung in order to understand
the pathological consequences of infection of such cell types.
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